Biotech · Public company · Calabasas, CA, US
Neonc Technologies Holdings, Inc.
Ticker NTHI · SEC CIK 0001979414
Track this companyFree. Adds Neonc Technologies Holdings, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials44 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- CarboplatinPhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- NEO100Phase 2 · Residual, Progressive or Recurrent Grade II or III MeningiomaClinicalTrials.gov · fetched Nov 12, 2026
- NEO212 Oral CapsulePhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- Perillyl alcoholPhase 2 · Glioblastoma MultiformeClinicalTrials.gov · fetched Nov 12, 2026
- RegorafenibPhase 2 · Diffuse Astrocytoma, IDH-MutantClinicalTrials.gov · fetched Nov 12, 2026
- NEO100Phase 1 · Pediatric Tumor of CNSClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsPHASE1 · RECRUITING · started Sep 8, 2026ClinicalTrials.gov NCT06357377 · fetched Nov 12, 2026
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisPHASE1_PHASE2 · RECRUITING · started Nov 1, 2023ClinicalTrials.gov NCT06047379 · fetched Nov 12, 2026
- NEO100 and High-Grade MeningiomaPHASE2 · RECRUITING · started Jul 1, 2022ClinicalTrials.gov NCT05023018 · fetched Nov 12, 2026
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 1, 2017ClinicalTrials.gov NCT02704858 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Aug 21, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
NIH awards3
- Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant GliomasFiscal year 2026 · $1MNIH RePORTER 5R42CA246902-04 · fetched Nov 12, 2026
- Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid LeukemiaFiscal year 2025 · $400KNIH RePORTER 6R41CA271879-02 · fetched Nov 12, 2026
- Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant GliomasFiscal year 2025 · $1MNIH RePORTER 6R42CA246902-03 · fetched Nov 12, 2026